Harmony Biosciences Holdings, Inc. is a U.S.-based neuroscience company focused on rare neurological diseases, with its commercial business anchored by WAKIX (pitolisant) for narcolepsy. The company is expanding beyond sleep/wake disorders into rare epilepsy and neurobehavioral conditions through internal development and collaborations such as its 2025 CiRC Biosciences agreement.
77,2 %
18,3 %
+21,5 %
3.60
3.58
| % | |
|---|---|
| Commercial product: WAKIX | 90% Commercial sales of WAKIX, the company's approved pitolisant therapy for narcolepsy. |
| Pipeline development | 5% Internal R&D for pitolisant formulations and new neuroscience candidates. |
| Collaborative R&D and licensing | 5% Research collaborations, options, and licenses such as the CiRC agreement. |
Harmony sells primarily into the U.S. specialty pharmaceutical channel, where payers, specialty pharmacies, and...
Specialty pharmacies such as Accredo and PANTHERx dispense WAKIX and manage patient access and fulfillment.
Commercial, Medicare, and Medicaid plans influence formulary access and reimbursement for WAKIX.
Narcolepsy-treating HCPs prescribe WAKIX based on efficacy, tolerability, and non-controlled status.
Patients use WAKIX for excessive daytime sleepiness and cataplexy, driving repeat prescription demand.
Potential future patients for pipeline assets if development programs succeed.
Harmony is headquartered in the United States and its commercial business is overwhelmingly U.S...
Harmony is trying to reduce dependence on a single commercial asset by extending the pitolisant franchise and building...
The company remains highly dependent on one approved product, so share gains and access expansion are critical.
New formulations can extend the franchise, improve differentiation, and support lifecycle management.
Pipeline diversification reduces single-product risk and creates longer-term growth options.
Harmony’s biggest risk is concentration: the company is substantially dependent on WAKIX, so any slowdown in...
The company states it is substantially dependent on its only approved product, so any decline in WAKIX sales would directly hit revenue and cash generation.
WAKIX depends on a limited number of API and finished-dose suppliers, increasing the risk of shortages, delays, or quality issues.
Pipeline assets and new formulations may not demonstrate sufficient efficacy, safety, or bioequivalence to support approval or commercialization.
Net revenue depends on discounts, rebates, and formulary access, which can change with payer negotiations and patient mix.
Pharmaceutical products face FDA oversight, labeling changes, safety monitoring, and commercialization compliance requirements.
: 28.4.2026